CombiMatrix Reports First Quarter 2017 Financial And Operating Results

IRVINE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces financial results for the three months ended March 31, 2017 and provides a business update.

“We are delighted to be reporting another quarter of exceptional financial and operational performance,” said Mark McDonough, CombiMatrix President and CEO. “Revenues increased 27% year-over-year to $3.8 million, driven by a 32% increase in our reproductive health segment. Gross margin on diagnostic services improved to 59.9% from 51.6% a year ago, cash collections reached a record $3.4 million, and net loss decreased to $518,000, a nearly $1 million improvement from the prior year. We believe that we are tracking very well toward reaching our goal of positive cash flows from operations by the fourth quarter of 2017.

MORE ON THIS TOPIC